title: Hepatitis C treatment and liver cancer recurrence: cause for concern?
authors.affiliation: Department of Medicine, University of Minnesota, Minneapolis, MN, USA. Electronic address: debes003@umn.edu.
authors.forename: Jose D
authors.initials: JD
authors.lastname: Debes
authors.affiliation: Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, ON, Canada.
authors.forename: Harry L A
authors.initials: HL
authors.lastname: Janssen
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
authors.forename: Andre
authors.initials: A
authors.lastname: Boonstra
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D056747:Immunomodulation; D008113:Liver Neoplasms / Q000276:immunology*; D009364:Neoplasm Recurrence, Local / Q000276:immunology*
chemical_list: D000998:Antiviral Agents